國泰集團(603977.SH):前三季度淨利潤預增20%-30%
格隆匯10月18日丨國泰集團(603977.SH)公佈,公司預計2022年前三季度實現歸屬於上市公司股東的淨利潤約為1.88億元至2.04億元,同比增加20%至30%;預計公司2022年前三季度實現歸屬於上市公司股東的扣除非經常性損益的淨利潤約為1.73億元至1.88億元,同比增加20%至30%。
本期業績預增的主要原因:
1、報吿期內,受益於工業炸藥銷售均價上漲及電子數碼雷管銷量增長,帶動公司民爆業務板塊穩步增長;
2、公司控股子公司江西國泰利民信息科技有限公司、江西永寧科技有限責任公司、江西拓泓新材料有限公司等公司營業收入和利潤規模較上年同期均有較大幅度增長,拉動公司非民爆業務板塊業績持續增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.